Eric Lefkofsky has already built an empire on data and technology — Groupon made him a billionaire, while other ventures spanned logistics, advertising, and e-commerce. But when his wife was diagnosed with breast cancer, the usual business logic broke down: medicine held mountains of information that could not be used for a specific patient. This gap became not merely a personal pain but the starting point for a new chapter in his career.
In 2015, Lefkofsky founded Tempus AI. The company does not simply collect genomic and clinical data — it builds an infrastructure in which every case of treatment makes the system smarter for the next patient. Unlike consumer startups, where success is measured by speed and reach, here precision, evidence, and trust become the key factors. A mistake in healthcare costs not lost users but human lives.
By the second quarter of 2026, Tempus reported revenue of 382,5 million dollars — growth of 22 percent year over year. Oncology testing volumes rose by 31 percent, while the data licensing and modeling business grew by 36 percent. The company raised its full-year guidance to 1,6 billion dollars. Behind these figures lies more than diagnostics: Tempus unites physicians, researchers, and pharmaceutical companies into a single ecosystem in which data becomes the primary asset.
The acquisitions of 2026 — Personalis, Paige, and Center Health — expand its reach from oncology to cardiology, diabetes, and digital pathology. Lefkofsky emphasizes that AI in healthcare delivers the greatest returns precisely because the data here are fragmented and unstructured. Models trained on millions of records identify patterns that are inaccessible to an individual physician. This is not a replacement for specialists but a tool that makes every decision better informed than the last.
For investors and entrepreneurs, the story of Tempus illustrates a shift: from quick consumer wins to long-term systemic projects, where value is measured not only by profit but also by impact on the length and quality of life. Personal motives here intertwine with economic ones — the data collected today become the capital of tomorrow's discoveries and more precise therapies.
Unlike the Groupon era, where success depended on virality and geographic expansion, Tempus requires patience and evidence. Yet the payoff is potentially higher: when information about thousands of patients helps one, medicine ceases to be a lottery and turns into a predictable system. Lefkofsky shows that true capital today is not only money but also the ability to turn scattered facts into collective intelligence that saves lives.
